Results 81 to 90 of about 40,867 (262)
Denosumab versus romosozumab for postmenopausal osteoporosis treatment
Scientific Reports, 2021 Denosumab and romosozumab, a recently approved new drug, are effective and widely known molecular-targeted drugs for postmenopausal osteoporosis treatment.
T. Kobayakawa +5 more
semanticscholar +1 more source
Incidence and Risk Factors of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients Having Undergone Autologous Stem Cell Transplantation [PDF]
, 2012 Background: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe complication of bisphosphonate therapy. Due to their long survival and subsequently high cumulative doses of bisphosphonates, multiple myeloma patients have the highest risk ...
Baumann, Philipp +9 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.This original research used medication administration data to explore adherence to treatment guidelines for the most common osteoporosis medications in long‐term residential aged care (RAC) in Australia. The paper highlights gaps in adherence to treatment guidelines that must be addressed to improve outcomes of older adults living in RAC.
Marea O'Donnell +7 more
wiley +1 more source
Osteoporosis InternationalThis 78-week (18-month) study conducted in 479 postmenopausal women with osteoporosis evaluated the efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of candidate biosimilar CT-P41 relative to US reference denosumab.
J. Reginster +17 more
semanticscholar +1 more source
Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
Current Osteoporosis Reports, 2022 Purpose of Review Inhibition of receptor activator of nuclear factor kappa-B ligand (RANKL) with denosumab is an effective treatment in a number of conditions including osteoporosis where suppression of bone resorption is desired.
Albert S. Kim, C. Girgis, M. McDonald
semanticscholar +1 more source
BMEMat, EarlyView.This study develops a nano‐enzyme patch (ezPatch) targeting bone interfaces. Utilizing ligand‐to‐metal charge transfer (LMCT) catalysis and bone‐targeting ligands on copper nanosheets, ezPatch simultaneously scavenges reactive oxygen species (ROS) and generates oxygen in situ at bone‐losing sites.
Yi Chen +12 more
wiley +1 more source
Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab
Case Reports in Medicine, 2015 Giant cell tumor (GCT) of bone is a generally benign, but often locally aggressive, neoplasm of bone, with a propensity for recurrence. Sarcomatous transformation is rare and typically occurs with a history of recurrences and radiation treatment ...
Cory Julian Broehm +3 more
doaj +1 more source
Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw [PDF]
, 2016 Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) is an intractable, though rare, complication in cancer patients with bone metastases and patients with osteoporosis who are treated with antiresorptive agents, including bisphosphonates and ...
Akira Taguchi +11 more
core +1 more source
Clinical Advances in Periodontics, EarlyView.Abstract Background Medication‐related osteonecrosis of the jaw (MRONJ) is a challenging complication associated with antiresorptive medications. Its exact pathophysiology remains unclear, but dental extractions and infections are known triggers, complicating prevention, and treatment.
Pedro Franco Ferreira +3 more
wiley +1 more source
Scientific ReportsThe present study aimed to compare clinical and radiological differences of ONFH patients who were treated with denosumab, and a control group. A total of 178 patients (272 hips) with symptomatic, nontraumatic ONFH were divided into a denosumab group (98
Jun-Ki Moon +5 more
doaj +1 more source